Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

First Wave BioPharma to Participate in BIO Partnering @JPM During "J.P. Morgan Week 2024" 

GlobeNewswire December 6, 2023

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference

GlobeNewswire December 5, 2023

Date and Time Announced for First Wave BioPharma CEO James Sapirstein's Presentation at the 2023 BIO Investor Forum

GlobeNewswire October 10, 2023

First Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities Conference

GlobeNewswire October 3, 2023

First Wave BioPharma To Present at the BIO Investor Forum

GlobeNewswire September 15, 2023

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market

GlobeNewswire September 14, 2023

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

GlobeNewswire September 14, 2023

First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering

GlobeNewswire July 19, 2023

First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation

GlobeNewswire July 13, 2023

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

GlobeNewswire July 5, 2023

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

GlobeNewswire June 28, 2023

First Wave BioPharma Strengthens Intellectual Property Estate

GlobeNewswire June 27, 2023

First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)

GlobeNewswire June 15, 2023

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market

GlobeNewswire June 13, 2023

First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis

GlobeNewswire June 13, 2023

First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference

GlobeNewswire May 15, 2023

First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

GlobeNewswire May 11, 2023

First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference

GlobeNewswire May 2, 2023

First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

GlobeNewswire April 25, 2023